TVTX
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a significant premium to book value, but looks cheap on a forward earnings basis.
- Low Forward P/E (8.84)
- Extreme P/B ratio (31.90)
- High P/S ratio (7.58)
Growth metrics are top-tier for the healthcare sector.
- 73% Revenue growth
- Positive earnings trajectory
- Strong price momentum (+166% 1Y)
- Dependence on biotech pipeline success
The company has successfully pivoted from a loss-making R&D phase to a growth phase.
- Consistent earnings beats in the last 4 quarters
- Massive average surprise (339%)
- History of deep losses prior to 2024
Liquidity is strong, but the balance sheet is burdened by debt.
- Piotroski F-Score 4/9 (Stable)
- Strong Quick Ratio (2.53)
- High Debt/Equity (2.86)
- Negative ROE (-57.8%)
Typical for growth-stage biotechnology companies.
- No dividend payout
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TVTX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TVTX
Travere Therapeutics, Inc.
Primary
|
+55.7% | +89.8% | +166.6% | +44.5% | +50.1% | +31.2% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
|
TLX
Telix Pharmaceuticals Limited
Peer
|
-29.2% | -29.2% | -33.8% | -0.6% | +22.6% | -4.5% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TVTX
Travere Therapeutics, Inc.
|
BULLISH | $3.72B | - | -57.8% | -5.2% | $40.29 | |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
|
TLX
Telix Pharmaceuticals Limited
|
NEUTRAL | $3.64B | - | -1.9% | -0.9% | $10.73 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TVTX from our newsroom.